- New
-
Topics
- All Categories
- Metaphysics and Epistemology
- Value Theory
- Science, Logic, and Mathematics
- Science, Logic, and Mathematics
- Logic and Philosophy of Logic
- Philosophy of Biology
- Philosophy of Cognitive Science
- Philosophy of Computing and Information
- Philosophy of Mathematics
- Philosophy of Physical Science
- Philosophy of Social Science
- Philosophy of Probability
- General Philosophy of Science
- Philosophy of Science, Misc
- History of Western Philosophy
- Philosophical Traditions
- Philosophy, Misc
- Other Academic Areas
- Journals
- Submit material
- More
From experience to design – The science behind Aspirin
Abstract
How does aspirin reduce pain and inflammation? How does it prevent heart attacks? Why does it upset the stomach? How do scientists discover the answers? This article examines research and development in the history from willow bark to aspirin to “super aspirins” Celebrex and Vioxx. Scientists adopt various approaches: trial and error, laboratory experiment, clinical test, elucidation of underlying mechanisms, concept-directed research, and rational drug design. Each approach is limited, but they complement each other in unraveling the mystery of a wonder drug.Other Versions
No versions found
Links
PhilArchive
External links
(no proxy)
Setup an account with your affiliations in order to access resources via your University's proxy server
Through your library
- Only published works are available at libraries.
My notes
Similar books and articles
Integrating research and development: the emergence of rational drug design in the pharmaceutical industry.Matthias Adam - 2005 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 36 (3):513-537.
Integrating research and development: the emergence of rational drug design in the pharmaceutical industry.Matthias Adam - 2005 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 36 (3):513-537.
Vioxx and other pharmaceutical product withdrawals: ethical issues in ensuring the integrity of drug and medical device research, development and commercialization.K. L. Phua & F. I. Achike - 2007 - Clinical Ethics 2 (3):155-162.
Conflict of interest as seen from a researcher’s perspective.Arrigo Schieppati, Norberto Perico & Giuseppe Remuzzi - 2002 - Science and Engineering Ethics 8 (3):337-342.
Aspirin and Diabetes Care in Nigeria: Treatment or Exploitation?Okoro E. O. Oyejola - 2015 - Journal of Clinical Research and Bioethics 6 (4).
Binding Specificity and Causal Selection in Drug Design.Oliver M. Lean - 2020 - Philosophy of Science 87 (1):70-90.
Community equipoise and the architecture of clinical research.Jason H. T. Karlawish & John Lantos - 1997 - Cambridge Quarterly of Healthcare Ethics 6 (4):385-.
Science in the Looking Glass:What Do Scientists Really Know?: What Do Scientists Really Know?E. Brian Davies - 2003 - New York: Oxford University Press UK.
Analytics
Added to PP
2010-12-22
Downloads
64 (#334,991)
6 months
2 (#1,696,787)
2010-12-22
Downloads
64 (#334,991)
6 months
2 (#1,696,787)
Historical graph of downloads
PhilPapers logo by Andrea Andrews and Meghan Driscoll.
This site uses cookies and Google Analytics (see our terms & conditions for details regarding the privacy implications). Use of this site is subject to terms & conditions.
All rights reserved by The PhilPapers Foundation
Server: philpapers-web-667477cd97-9l5tj dc2